You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 136 No. 2, February 1982 TABLE OF CONTENTS
  Archives
  •  Online Features
  LETTERS TO THE EDITOR
 This Article
 •References
 •Full text PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Second Malignancy in Acute Lymphocytic Leukemia

DANIEL M. GREEN, MD
Department of Pediatrics Roswell Park Memorial Institute 666 Elm St Buffalo, NY 14263

Am J Dis Child. 1982;136(2):175.

Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

Sir.—I read with interest the article "Second Malignancy in Acute Lymphocytic Leukemia: Review of 33 Cases" by Drs Mosijczuk and Ruymann in the JOURNAL (1981;135:313-316). In their article, they discussed the occurrence of histiocytic medullary reticulosis (HMR) after the diagnosis of acute lymphocytic leukemia (ALL). Histiocytic medullary reticulosis is a pattern of response to infection by a number of organisms.1,2 Although originally identified by Robb-Smith as one of the causes of HMR,3 acquired toxoplasmosis has been omitted from the list of possible causes of HMR in recent articles.

In the immunocompetent host, toxoplasmosis is a benign, self-limited illness that frequently resembles infectious mononucleosis in its clinical manifestations. However, in the immunosuppressed host, toxoplasmosis occurs as an acute, fulminating illness, with prominent systemic symptoms, hepatosplenomegaly, and, occasionally, signs of CNS dysfunction.4 If this diagnosis is not considered in an immunocompromised host, and appropriate therapy with pyrimethamine and . . . [Full Text PDF of this Article]



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1982 American Medical Association. All Rights Reserved.